1.24
+0.01(+0.81%)
Currency In USD
Address
1460 Broadway
New York City, NY 10036
United States of America
Phone
646 661 7661
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
May 05, 2017
| Name | Title | Pay | Year Born |
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Chief Executive Officer & Chairman | 931,422 | 1953 |
| Dr. Dirk Haasner | Senior Vice President of Global Manufacturing & CMC QA | 416,952 | 1965 |
| Mr. Jeffrey A. Rona | Chief Business and Financial Officer | 712,228 | 1968 |
| Ms. Margaret Alexander | President & Chief Operating Officer | 729,727 | 1981 |
| Mr. Zhong Zhong Ph.D. | Chief Scientific Officer | 0 | N/A |
| Mr. Tom Parry | Vice President of Research and Early Development | 0 | N/A |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development | 0 | 1975 |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer | 0 | N/A |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research | 0 | N/A |
| Ms. Victoria Fort | Senior Vice President of Corporate Affairs & Corporate Strategy | 0 | N/A |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.